viewPhysiomics PLC

Physiomics spies possible ‘nearer-term’ revenues from latest cancer tool

As part of an Innovate UK-funded project, Physiomics has developed a tool that could potentially help doctors work out how much of a chemotherapy drug should be prescribed to individual patients

iv drip in hospital
Physiomics received £68,000 from Innovate UK to cover the costs of the research

Physiomics Plc (LON:PYC) believes revenues from a tool it has developed as part of a project funded by Innovate UK could potentially be just around the corner.

Generally, doctors prescribe cancer patients with the same amount of a chemotherapy drug, but this can lead to under- or over-dosing individual patients, as each will respond differently.

As part of an Innovate UK-funded project, Physiomics has developed a tool that, from a simple blood test, could provide clinicians with a prediction of both toxicity and efficacy for any given dose.

READ: Renewal of key Merck contract caps off strong first half for Physiomics

They could then use this information to tailor the treatment to individual patients. This could potentially reduce the costs and morbidity associated with over-dosing, while it could also improve efficacy as a result of under-dosing.

Physiomics has said today it is exploring the approval of the tool as a medical device, although this would likely require further clinical validation before it could be commercialised.

But bosses pointed out that the tool could be used earlier in research settings, “thus creating the possibility of nearer term revenue potential”.

In support of the tool’s possible commercialisation, the AIM company is approaching potential strategic partners, clinical collaborators and grant providers to help it progress this “exciting opportunity”.

It has already presented a poster on the project at this year’s American Association for Cancer Research, which helped to drum up interest, while it has also spoken with the Oxford Academic Health Sciences Network and the National Institute for Health Research signposting service.

Physiomics cautioned that there is no guarantee this project will progress, although they will make an announcement later in the year should anything come of its discussions.

Quick facts: Physiomics PLC

Price: 2.604 GBX

Market: AIM
Market Cap: £1.87 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Thor Mining's Mick Billing at Tungsten conference as further...

Thor Mining PLC's (LON:THR) Mick Billing skypes into the Proactive London studio from the International Tungsten Industry Association conference in Stresa, Italy. His trip conincides with the start of a second drill campaign at its Bonya tungsten deposits in Northern Territory of Australia...

1 hour, 27 minutes ago

2 min read